Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3543)	7/14/2003 12:45:12 PM
From: keokalani'nui	Respond to of 4974

Onyx Announces Public Offering of Common Stock Monday July 14, 7:01 am ET RICHMOND, Calif., July 14 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced that it plans to publicly offer 4,000,000 shares of its common stock pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. The company also intends to grant to the underwriters in connection with the offering an option to purchase up to an additional 600,000 shares of common stock. All of the shares are being sold by Onyx. Morgan Stanley & Co. Incorporated, together with Lehman Brothers and SG Cowen Securities Corporation are acting as the underwriters for the offering. Morgan Stanley will serve as sole bookrunner for the offering.

To: scaram(o)uche who wrote (3543)	7/16/2003 3:57:18 AM
From: nigel bates	Respond to of 4974

With Onyx and this, we must now be up to 'P' at the very least... THE WOODLANDS, Texas, July 16 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) today announced it plans to sell 10.0 million shares of its common stock pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. The underwriters have the option to purchase up to an additional 1.5 million shares of common stock from Lexicon to cover over-allotments, if any. Lexicon currently intends to use the net proceeds for research and development. The offering will be joint lead managed by Morgan Stanley & Co. Incorporated and UBS Securities LLC. CIBC World Markets Corp. and Punk, Ziegel & Company, L.P. will also serve as managing underwriters for the offering. Morgan Stanley will serve as sole bookrunner for the offering.